BioSpace News Archive

The U.S. Food and Drug Administration is announcing draft guidance for industry on action levels for lead in processed foods that are intended for babies and children under two years of age, to help reduce potential health effects in this vulnerable population from dietary exposure to lead.

GreenLab, Inc. announces closing a $5,268,944.44 seed funding round.

Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 8th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis.

Magnolia Medical Technologies, Inc. (“Magnolia Medical”), inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®), the only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination for sepsis testing accuracy1, today shared the publication of recent clinical results from the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas.

The Phase 3 study conducted in the U.S. will assess the efficacy and safety of the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine for the treatment of patients with schizophrenia.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share of the company’s common stock for the second quarter of 2023.

The Japan Prize Foundation announced the winners of the 2023 Japan Prize on January 24, 2023.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a positive regulatory update for D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs).

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced it has entered into a managed care provider agreement with Medical Cost Containment Professionals LLC to process out-of-network claims for PreludeDx’s DCISionRT® test.

Metagenics, Inc. (“Metagenics” or the “Company”), a leading global nutritional supplement company, today announced that it named Gavin J. Lindberg as Chief Financial Officer, effective January 17.